Vanguard Group Inc Compugen LTD Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.68 - $1.11 $1.59 Million - $2.6 Million	-2,342,483 Reduced 95.52%	109,817 $76,000
Q3 2022 Nov 14, 2022	BUY	$0.66 - $2.32 $20,755 - $72,957	31,447 Added 1.3%	2,452,300 $1.61 Million
Q2 2022 Aug 12, 2022	SELL	$1.57 - $3.33 $67,087 - $142,294	-42,731 Reduced 1.73%	2,420,853 $4.48 Million
Q1 2022 May 13, 2022	BUY	$2.76 - $4.64 $318,854 - $536,045	115,527 Added 4.92%	2,463,584 $7.93 Million
Q4 2021 Feb 14, 2022	BUY	$4.09 - $7.16 $142,671 - $249,762	34,883 Added 1.51%	2,348,057 $10.1 Million
Q2 2021 Aug 13, 2021	BUY	$6.87 - $9.16 $15.9 Million - $21.2 Million	2,313,174 New	2,313,174 $19.2 Million

13.3M

191K

135K

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $142M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.